Over 100 pharmaceutical patents are set to expire by end-2009, including those for 13 major products, and the Big Pharma firms which will be most affected are GlaxoSmithKline and Pfizer, followed by Novartis and Takeda. However, only a few of the newly off-patent products will show sufficient viability and market potential for generic drugmakers to pursue, according to new forecasts from Global Insight.
2008 saw some high-value drugs go off-patent - including Merck & Co's Fosamax (alendronate), Pfizer's Camptosar (irinotecan) and Wyeth's Effexor XR (venlafaxine) - widening the market presence of generics drug makers and creating an unexpected dent in the revenue structure of several Big Pharma players, says the report.
More
No comments:
Post a Comment